Ovarian cancer biomarkers: current options and future promise.
Ovarian cancer biomarkers: current options and future promise.
复制标题
DOI：
10.6004/jnccn.2008.0059
复制
发表时间：
2008-09
期刊：
影响因子：
--
通讯作者：
Moses MA
中科院分区：
文献类型：
--
作者：
Coticchia CM;Yang J;Moses MA
近年来，随着更有效、毒性更低的癌症药物进入患者群体，对准确和可靠的癌症诊断和预后的需求已被广泛认识到。没有任何地方比卵巢癌更需要这种治疗，因为大多数女性都是在疾病进展的后期被确诊的。能够灵敏和特异地预测早期疾病的存在、状态、分期和相关的治疗效果，可能会给卵巢癌的检测和治疗带来革命性的变化。在这里，我们回顾了当前卵巢癌的诊断和预后，以及正在研究和验证的潜在的卵巢癌生物标志物。我们还介绍了一些最新的分子方法，用于识别可能代表下一代卵巢癌诊断和预后的基因和蛋白。
In recent years, as more effective, less toxic cancer drugs reach the patient population, the need for accurate and reliable cancer diagnostics and prognostics has become widely appreciated. Nowhere is this need more dire than in ovarian cancer, where the majority of women are diagnosed late in the course of disease progression. The ability to sensitively and specifically predict the presence of early disease, its status, stage, and associated therapeutic efficacy, has the potential to revolutionize ovarian cancer detection and treatment. Here, we review current ovarian cancer diagnostics and prognostics as well as potential ovarian cancer biomarkers that are being studied and validated. We also present some of the most recent molecular approaches being used to identify genes and proteins that may represent the next generation of ovarian cancer diagnostics and prognostics.